Skip to main content
. 2016 Jun 16;11(6):e0157376. doi: 10.1371/journal.pone.0157376

Fig 5. JAK-STAT6 inhibitors decrease IL-13-induced eotaxin-3 expression in esophageal fibroblasts.

Fig 5

IL-13-induced (a) STAT6 phosphorylation, (b) eotaxin-3 mRNA, and (c) eotaxin-3 protein expression are decreased in esophageal fibroblasts, following treatment with JAK-STAT6 inhibitors (AS1517499 and leflunomide). (d) Selective JAK1/2 inhibitor ruxolitinib blocked IL-13-induced eotaxin-3 protein secretion. Densitometry values are normalized to their respective loading controls (β tubulin or GAPDH). Data are the means ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.